ArriVent Biopharma, Inc.

About ArriVent Biopharma, Inc.

ArriVent BioPharma, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative oncology therapies, primarily targeting non-small cell lung cancer (NSCLC) with uncommon EGFR mutations. Its lead product, firmonertinib, is an oral, mutant-selective tyrosine kinase inhibitor designed to address unmet needs in EGFR-mutated NSCLC, including exon 20 insertion and PACC mutations. The company also develops next-generation antibody drug conjugates (ADCs) for solid tumors, leveraging global partnerships and in-licensing strategies.